Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Executive Summary
Using Pharmapremia data, we analyze performance metrics for a select group of leading cancer companies to see where the sticking points are and who is winning at industry’s most important race.
As oncology drug development programs skyrocket and companies prioritize the therapeutic area, there’s a need to understand what is working and where the process needs to be improved.
Using performance metrics from Informa Pharma Intelligence’s Pharmapremia on transitions between clinical phases and the likelihood of approval from 2006-2010 and 2011-2015, it’s clear that as the number of cancer development programs has risen, success rates aren’t holding up.
“Despite the fact that more oncology candidates transitioned through and out of company pipelines over the last five years compared to the previous five, overall success rates took a dive industry-wide,” Informa Pharma Consulting’s Justin Burns said. “These data underscore just how dedicated the pharmaceutical industry has been, especially the major companies, to advancing the treatment paradigm for cancer.”
While performance was down strictly looking at success rates, Burns noted that for select companies that have concentrated on cancer, there has been an increase in overall approvals, from 39 to 52 for 2006-2010 and 2011-2015, respectively. “Despite the fact that the harder they tried, the more they failed, these companies continued to devote considerable R&D spend to their cancer pipelines,” he commented.
See below for more on which companies are standing above the pack and which areas have the best odds to make it to market.
Oncology Scorecard
Biomedtracker: follow the drug development process
03 Apr 2017
Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.
Scrip: industry news and insights
Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.
Topics Policy and regulation
Scrip: industry news and insights
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018. <br />
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
From discovery to patent expiry, and coverage spanning both ethical and generic drugs, Medtrack has you covered. Stay current on key financing, drug and biologics development and drug manufacturing information, all with a single tool.
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Looking for more products Product Finder
